Buy-rated reports

511 tickers rated Buy
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Curtiss-Wright Corporation
CW·Industrials
A ★★★★Buy
Current$463.47
Target$525.00
Return+13.3%
Nov 7, 2026

Curtiss-Wright combines durable defense and nuclear franchises with rising returns on capital and improving cash flow, while procurement delays, leadership transitions, and valuation sensitivity remain material risks.

Score
83
BP p.l.c.
BP·Energy
A ★★★★Buy
Current$50.39
Target$55.25
Return+9.6%
Nov 2, 2026

BP's improving balance sheet, attractive cash-flow valuation and disciplined capital allocation create meaningful upside potential, although cyclical oil prices and unusually strong refining profits threaten earnings sustainability.

Score
83
Cboe Global Markets, Inc.
CBOE·Financials
A ★★★★Buy
Current$346.36
Target$363.40
Return+4.9%
Nov 2, 2026

Cboe's proprietary index-derivatives network, strong margins, and durable licensing moat support long-term earnings compounding, but elevated expectations and dependence on trading activity constrain near-term upside.

Score
83
Gen Digital Inc.
GEN·Technology
A ★★★★Buy
Current$29.13
Target$32.45
Return+11.4%
Nov 2, 2026

Gen combines durable cybersecurity subscription cash flows with expanding financial-wellness opportunities and an attractive earnings valuation, although substantial leverage and platform competition constrain its upside.

Score
83
Erie Indemnity Company
ERIE·Financials
A ★★★★Buy
Current$261.39
Target$283.20
Return+8.3%
Nov 1, 2026

Erie Indemnity offers a durable, cash-generative insurance management franchise at a valuation below historical norms, although concentrated governance, CEO succession, and subdued earnings growth limit its near-term upside.

Score
83
T. Rowe Price Group, Inc.
TROW·Financials
A ★★★★Buy
Current$103.90
Target$120.75
Return+16.2%
Nov 1, 2026

T. Rowe Price offers strong cash generation, a substantial dividend, and an inexpensive valuation supported by a resilient balance sheet, although persistent client outflows and passive-investing competition threaten long-term earnings growth.

Score
83
ResMed Inc.
RMD·Healthcare
A ★★★★Buy
Current$229.94
Target$254.10
Return+10.5%
Nov 1, 2026

ResMed combines a durable sleep therapy franchise, recurring mask revenue, and high cash returns with a relatively attractive valuation, although evolving treatment alternatives and operating-margin pressure could constrain future earnings growth.

Score
83
L3Harris Technologies, Inc.
LHX·Industrials
A ★★★★Buy
Current$277.61
Target$319.55
Return+15.1%
Nov 1, 2026

L3Harris offers durable defense demand, record backlog and improving cash generation at attractive cash-flow multiples, although missile production execution, capital intensity and governance changes remain material risks.

Score
83
TotalEnergies SE
TTE·Energy
A ★★★★Buy
Current$95.33
Target$101.97
Return+7.0%
Nov 1, 2026

TotalEnergies combines strong cash generation, LNG growth opportunities and attractive shareholder distributions with a moderate valuation, although oil-price cyclicality and large-project execution risks constrain sustainable upside.

Score
83
Fomento Económico Mexicano, S.A.B. de C.V.
FMX·Consumer Staples
A ★★★★Buy
Current$126.10
Target$136.40
Return+8.2%
Oct 31, 2026

FEMSA combines OXXO's dominant convenience-store network and Coca-Cola FEMSA's cash-generative bottling operations with attractive cash-flow valuation, although weak European and pharmacy margins could limit consolidated earnings growth.

Score
83
Agnico Eagle Mines Limited
AEM·Materials
A ★★★★Buy
Current$165.38
Target$187.50
Return+13.4%
Oct 31, 2026

Agnico Eagle combines a high-quality gold mining portfolio, strong net cash and profitable development opportunities, but volatile gold prices, rising unit costs and execution risks could materially affect future cash flow.

Score
83